Digestive Health
Benaroya Research Institute and Virginia Mason Medical Center conduct clinical trials to improve digestive health. The Center for Digestive Health at the Virginia Mason Medical Center is internationally known for bringing together experts to optimize care through innovations in research, education and a multidisciplinary approach to the treatment of digestive diseases.
Clinical Research Studies in Digestive Health
We have ongoing clinical research studies in several areas of digestive health. Studies labeled as “Enrolling” are actively recruiting new participants while studies labeled as “Closed to Enrollment” are still active but no longer seeking new participants.
Please email Digestive Health Research or call (206) 341-1021 for more information.
- Biliary and Liver Disease
A Multicenter, Prospective Study of EUS-Guided Transluminal Gallbladder Drainage in Patients with Acute Cholecystitis as an Alternative to Percutaneous Gallbladder Drainage
Principal Investigator: Shayan Irani, MD
Status: Closed to EnrollmentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis
Principal Investigator: Asma Siddique, MD
Status: Closed to Enrollment- Crohn's Disease
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease
Principal Investigator: Tim Zisman, MD
Status: EnrollingA Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn's Disease Who Have participated in ADMIRE II Study
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Status: Closed to EnrollmentA Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to severely active Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn's disease over a period of 24 weeks and a follow up period up to 52 weeks. ADMIRE-CD II study
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentCrohn's Disease: Risankizumab versus Ustekinumab for Subjects with Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentGA29145-An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severly Active Crohn's Disease Previously Enrolled in the Etrolizumab Phase II PRotocol GA29144
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentPhase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn's Disease
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment- Diverticulitis
Protocol for the Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial
Principal Investigator: Val Simianu, MD
Status: Enrolling- Non Alcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis due to NASH
Principal Investigator: Asma Siddique, MD
Status: Closed to EnrollmentA Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatoohepatitis
Principal Investigator: Asma Siddique, MD
Status: Closed to EnrollmentA Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
Principal Investigator: Asma Siddique, MD
Status: Closed to Enrollment- Pancreatitis
SHARP Trial SpHincterotomy for Acute Recurrent Pancreatitis Trial
Principal Investigator: Andrew Ross, MD
Status: EnrollingNI03-001-A Phase 1, Single Dose PK and Safety Study with NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 Compared to Placebo in Subjects with Chronic Pancreatitis
Principal Investigator: Shayan Irani, MD
Status: Closed to EnrollmentStent vs. Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial A Multicenter Randomized Non-inferiority Clinical Trial of Rectal Indomethacin Alone vs. Indomethacin & Prophylactic Pancrea
Principal Investigator: Joanna Law, MD
Status: Closed to Enrollment- Patients Having an Endoscopic Retrograde Cholangiopancreatography (ERCP)
Global Prospective Case Series using a Single-Use Duodenoscope
Principal Investigator: Andrew Ross, MD
Status: Closed to EnrollmentInitial Case Series with Exalt Single-Use Duodenoscope – Expanded User Experience
Principal Investigator: Andrew Ross, MD
Status: Closed to Enrollment- Ulcerative Colitis
A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: EnrollingA Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentA Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderate to Severe Ulcerative Colitis
Principal Investigator: James Lord, MD
Status: Closed to EnrollmentA Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to EnrollmentAn Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
Principal Investigator: Tim Zisman, MD
Status: Closed to Enrollment
Digestive Health Clinical Research Team Leadership

Laura Lockshon
Digestive Health Clinical Research Team Members

Emily Chesterfield

Brooke Grubb

Audrey Merz

Micaela Rodriguez Moncayo

Cheryl Shaw
